Category Drug bios
This was published just yesterday: Gilead Profit Triples, Hepatitis C Drug Revenue Reaches $2.3B http://www.foxbusiness.com/industries/2014/04/22/gilead-profit-triples-hepatitis-c-drug-revenue-reaches-23b/ Admiration to Henry Waxman (House of representatives) asking Gilead to explain the pricing of the drug!
Yesterday, April 10th, we had an inspiring and motivating call with Rachel Kiddell-Monroe. She has agreed to be our “Drug Bio Advisor”, saying she thinks the project is extremely important for UAEM’s advocacy work! She said that finding information for the drug bios is challenging and that a bit of detective work will be required […]
Wondering why the Drug Bio Project are looking at Hepatitis C drug? Well look no further, here is the answer! (We’ve caught a big fish)
Have a good read HERE ! If one of those Hepatitis C vaccine/drug down the pipeline somehow is linked to public finance, we might have caught a HUUUGE FISH ! Lets make an end to these (most definitely) high prices and fight for access to medicines for all ! Join our call, Thursday 27/02/2014 at 19 […]
We have finally set the date for our first open call to get this project going! Be there next Thursday, February 27th at 7pm GMT to launch the amazing, evidence-generating drug bio project that will alter UAEM’s work forever! After weeks of preliminary work, developing a methodology and discussing potential drugs with MSF, we are now ready to […]
On February 7th, Rosa and Benjamin had a meeting with Judit Rius and Rohit Malpani from MSF Access to medicines campaign. Attending was also Rachel Kiddel-Monroe and Bryan Collinsworth. Drug bios was enthusiastically discussed and MSF gave us a list of potential drugs to look into. This list includes drugs for HIV, TB resistance, HPV […]
Last weekend, February 7th to 9th, we attended the UAEM Winter Leadership Meeting in New York City. We got great input and encouraging feedback from fellow UAEMers from all over the world! We also managed to arrange a meeting with Médecins Sans Frontières (MSF). On Friday, 7th, we met with Judit Rius Sanjuan, US Manager of […]